Clinical trial
"A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"
NCT04932291 is registered in ClinicalTrials.gov with Oryzon Genomics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- "A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"
- Lead sponsor
- Oryzon Genomics S.A.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 26, 2021
- Completion date
- November 13, 2023
- Enrollment
- 211 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.